349 related articles for article (PubMed ID: 21999224)
21. The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.
Nagstrup AH
Acta Ophthalmol; 2023 Dec; 101 Suppl 278():3-21. PubMed ID: 38037546
[TBL] [Abstract][Full Text] [Related]
22. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
[TBL] [Abstract][Full Text] [Related]
23. The preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cells.
Paimela T; Ryhänen T; Kauppinen A; Marttila L; Salminen A; Kaarniranta K
Mol Vis; 2012; 18():1189-96. PubMed ID: 22605930
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulation.
Pauly A; Roubeix C; Liang H; Brignole-Baudouin F; Baudouin C
Invest Ophthalmol Vis Sci; 2012 Dec; 53(13):8172-80. PubMed ID: 23150620
[TBL] [Abstract][Full Text] [Related]
25. Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost.
Kumar S; Singh T; Ichhpujani P; Vohra S
Rom J Ophthalmol; 2019; 63(3):249-256. PubMed ID: 31687627
[No Abstract] [Full Text] [Related]
26. In vivo corneal epithelial permeability following treatment with prostaglandin analogs [correction of analoges] with or without benzalkonium chloride.
McCarey B; Edelhauser H
J Ocul Pharmacol Ther; 2007 Oct; 23(5):445-51. PubMed ID: 17941807
[TBL] [Abstract][Full Text] [Related]
27. From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability.
Rossi GC; Scudeller L; Rolle T; Pasinetti GM; Bianchi PE
Expert Opin Drug Saf; 2015 May; 14(5):619-23. PubMed ID: 25759110
[TBL] [Abstract][Full Text] [Related]
28. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
29. In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells.
Kahook MY; Ammar DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):259-63. PubMed ID: 20565312
[TBL] [Abstract][Full Text] [Related]
30. Duration of IOP reduction with travoprost BAK-free solution.
Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system.
Yee RW; Norcom EG; Zhao XC
Adv Ther; 2006; 23(4):511-9. PubMed ID: 17050493
[TBL] [Abstract][Full Text] [Related]
32. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
Crichton AC; Vold S; Williams JM; Hollander DA
Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
[TBL] [Abstract][Full Text] [Related]
33. Effects of polyquaternium- and benzalkonium-chloride-preserved travoprost on ocular surfaces: an impression cytology study.
Sezgin Akçay Bİ; Güney E; Bozkurt TK; Topal CS; Akkan JC; Ünlü C
J Ocul Pharmacol Ther; 2014 Sep; 30(7):548-53. PubMed ID: 24901262
[TBL] [Abstract][Full Text] [Related]
34. A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study.
Tau J; Passerini MS; Del Papa M; Aguilar A; Berra A
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1941-1946. PubMed ID: 35015115
[TBL] [Abstract][Full Text] [Related]
35. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride.
Whitson JT; Cavanagh HD; Lakshman N; Petroll WM
Adv Ther; 2006; 23(5):663-71. PubMed ID: 17142200
[TBL] [Abstract][Full Text] [Related]
36. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
[TBL] [Abstract][Full Text] [Related]
37. Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions.
Kumagami T; Wakiyama H; Kusano M; Kajiyama A; Miura Y; Uematsu M; Yoneda A; Kurihara J; Suzuma K; Kitaoka T
J Ocul Pharmacol Ther; 2014 May; 30(4):340-5. PubMed ID: 24576066
[TBL] [Abstract][Full Text] [Related]
38. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
39. Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects.
Stewart WC; Stewart JA; Jenkins JN; Jackson AL
J Glaucoma; 2003 Dec; 12(6):475-9. PubMed ID: 14646682
[TBL] [Abstract][Full Text] [Related]
40. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study.
Pisella PJ; Debbasch C; Hamard P; Creuzot-Garcher C; Rat P; Brignole F; Baudouin C
Invest Ophthalmol Vis Sci; 2004 May; 45(5):1360-8. PubMed ID: 15111589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
